Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...
Muriel, from the Auxiliary of Social Life, works at the home of Mr. T, who has multiple sclerosis, in Pas de Calais, France, on June 11, 2023. (Astier / BSIP via AFP) (CN) — For people living with ...
Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs). The FDA has ...